BioCentury
ARTICLE | Finance

Zeroing in on immunity

Anokion working on less immunogenic drugs with CHF33M series A

May 12, 2014 7:00 AM UTC

Investors in Anokion S.A.'s CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well as novel autoimmune therapeutics with improved safety.

Last week's tranched round was led by Novartis Venture Fund; Novo Ventures and Versant Ventures, with participation from additional private investors...